NeuroBo Pharmaceuticals (NRBO) Competitors $1.04 -0.05 (-4.59%) As of 10/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NRBO vs. OMCC, OCTO, KFFB, GREE, JFU, MDBH, CNF, BTOG, BCG, and JNVRShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Old Market Capital (OMCC), Eightco (OCTO), Kentucky First Federal Bancorp (KFFB), Greenidge Generation (GREE), 9F (JFU), MDB Capital (MDBH), CNFinance (CNF), Bit Origin (BTOG), Binah Capital Group (BCG), and Janover (JNVR). These companies are all part of the "banking" industry. NeuroBo Pharmaceuticals vs. Its Competitors Old Market Capital Eightco Kentucky First Federal Bancorp Greenidge Generation 9F MDB Capital CNFinance Bit Origin Binah Capital Group Janover Old Market Capital (NASDAQ:OMCC) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap banking companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations. Which has higher earnings and valuation, OMCC or NRBO? Old Market Capital has higher revenue and earnings than NeuroBo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOld Market Capital$9.37M3.85-$5.15M-$0.79-6.77NeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/A Is OMCC or NRBO more profitable? NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Old Market Capital's net margin of -21.79%. Old Market Capital's return on equity of -7.01% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Old Market Capital-21.79% -7.01% -4.78% NeuroBo Pharmaceuticals N/A -189.12%-122.31% Do insiders & institutionals have more ownership in OMCC or NRBO? 39.9% of Old Market Capital shares are owned by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 50.4% of Old Market Capital shares are owned by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate OMCC or NRBO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Old Market Capital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor OMCC or NRBO? In the previous week, Old Market Capital had 3 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 3 mentions for Old Market Capital and 0 mentions for NeuroBo Pharmaceuticals. Old Market Capital's average media sentiment score of 0.24 beat NeuroBo Pharmaceuticals' score of 0.00 indicating that Old Market Capital is being referred to more favorably in the media. Company Overall Sentiment Old Market Capital Neutral NeuroBo Pharmaceuticals Neutral Which has more volatility & risk, OMCC or NRBO? Old Market Capital has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. SummaryOld Market Capital beats NeuroBo Pharmaceuticals on 10 of the 11 factors compared between the two stocks. Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.96M$977.73M$6.10B$10.55BDividend YieldN/A4.84%5.73%4.78%P/E RatioN/A1.2584.1027.14Price / SalesN/A29.97607.17131.40Price / CashN/A17.6437.8662.13Price / Book0.698.0312.236.58Net Income-$12.47M-$7.71M$3.32B$276.75M7 Day Performance0.97%-0.52%0.74%0.93%1 Month Performance-21.80%25.69%8.00%4.19%1 Year Performance-67.09%-11.84%71.13%35.40% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo PharmaceuticalsN/A$1.04-4.6%N/A-63.2%$8.96MN/A0.0010High Trading VolumeOMCCOld Market Capital0.8948 of 5 stars$5.08+1.8%N/A-13.1%$34.31M$13.09M-6.437News CoverageGap DownOCTOEightcoN/A$11.07+34.3%N/A+288.1%$33.71M$43.87M0.0035KFFBKentucky First Federal Bancorp0.6049 of 5 stars$4.11+4.2%N/A+13.0%$33.28M$19.74M205.8060Analyst ForecastHigh Trading VolumeGREEGreenidge GenerationN/A$2.12-3.6%N/A-25.3%$33.22M$59.53M0.00680Gap DownHigh Trading VolumeJFU9F1.4982 of 5 stars$2.71flatN/A+132.3%$31.91M$309.97M0.00740Analyst ForecastGap DownMDBHMDB Capital3.1158 of 5 stars$3.43-2.1%N/A-44.1%$31.85M$2.16M6.1240CNFCNFinance2.0897 of 5 stars$4.31-10.2%N/A-67.7%$29.56M$342.20M13.90900High Trading VolumeBTOGBit Origin0.695 of 5 stars$0.45-9.8%N/A-81.7%$26.60M$2.89M0.0010Analyst ForecastShort Interest ↓Gap DownBCGBinah Capital Group0.4096 of 5 stars$1.58-7.6%N/A-14.0%$26.23M$168.90M-13.17130Gap UpJNVRJanoverN/A$16.04+1.6%N/A+213.4%$25.34M$2.10M-6.2722High Trading Volume Related Companies and Tools Related Companies Old Market Capital Alternatives Eightco Alternatives Kentucky First Federal Bancorp Alternatives Greenidge Generation Alternatives 9F Alternatives MDB Capital Alternatives CNFinance Alternatives Bit Origin Alternatives Binah Capital Group Alternatives Janover Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRBO) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
